CAR T-Cell Therapy Saved My Life: Robyn's Non-Hodgkin Lymphoma Story | The Patient Story

Robyn was diagnosed with Diffuse Large B-Cell Lymphoma. Four years after going through R-CHOP chemotherapy, she relapsed and went through more chemotherapy, a stem cell transplant, and radiation. She relapsed a second time only 9 months after therapy. This time, she joined a clinical trial for CAR T-cell therapy. In this conversation, Robyn, a three-time DLBCL survivor, and two top lymphoma specialists, Dr. Tycel Phillips from the City of Hope and Dr. Joshua Brody from Mount Sinai, discuss the latest research and treatment options n the most common subtype of non-Hodgkin lymphoma: diffuse large B-cell lymphoma (DLBCL). Thank you to Genmab and AbbVie for their support of our patient education program. Full story & transcript → https://www.thepatientstory.com/medic... Join Our Community: Website : https://www.thepatientstory.com/ Facebook: @ThePatientStory Instagram: @ThePatientStory Twitter: @patient_story 02:06 - What is diffused large B-cell lymphoma. 03:54 - What are the different treatment options for DLBCL? 05:45 - What is the treatment for a patient who relapses in the first 6-12 months? 09:25 - What is CAR T-Cell Therapy? 11:54 - Benefits and challenges of CAR T-Cell Therapy. 13:46 - CAR T-Cell therapy for refractory patients #cancersurvivor #cancerstories #cancer #thepatientstory #dlbcl #lymsm #nonhodgkinlymphoma #lymphoma #lymphomasurvivor #lymphomaawareness #cancertreatments #cancerresearch